Archives of otolaryngology--head & neck surgery · 2003
Detection of Epstein-Barr virus in metastatic lymph nodes of patients with nasopharyngeal carcinoma and a primary unknown carcinoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakao Kazunari, Yuge Tadashi, Mochiki Masato, Nibu Ken-ichi, Sugasawa Masashi
Аннотация
BACKGROUND: Nasopharyngeal carcinoma is often associated with neck lymph node (LN) metastases, which in many cases is the only manifestation of this disease. The submucosal and infiltrative characteristics of nasopharyngeal carcinoma make this type of cancer difficult to diagnose. Nasopharyngeal carcinoma has also been reported to be strongly associated with the Epstein-Barr virus.
METHODS: We examined 36 nasopharyngeal carcinomas (from 30 primary sites and from 6 metastasized LNs), 13 metastasized LNs of other head and neck cancers, and 12 primary unknown neck metastases using an in situ hybridization technique.
RESULTS: In the nasopharyngeal carcinomas, in situ hybridization with an Epstein-Barr virus-encoded small RNA identified the Epstein-Barr virus in 20 (67%) of the 30 primary sites and in 3 (50%) of the 6 metastasized LNs. Epstein-Barr virus was not detected in metastasized LNs of other head and neck cancers, but was detected in 1 of the primary unknown neck metastases.
CONCLUSION: In situ hybridization using a digoxigenin-labeled Epstein-Barr virus-encoded small RNA probe is useful for the differential diagnosis of metastasized LNs when the primary site is unknown.
METHODS: We examined 36 nasopharyngeal carcinomas (from 30 primary sites and from 6 metastasized LNs), 13 metastasized LNs of other head and neck cancers, and 12 primary unknown neck metastases using an in situ hybridization technique.
RESULTS: In the nasopharyngeal carcinomas, in situ hybridization with an Epstein-Barr virus-encoded small RNA identified the Epstein-Barr virus in 20 (67%) of the 30 primary sites and in 3 (50%) of the 6 metastasized LNs. Epstein-Barr virus was not detected in metastasized LNs of other head and neck cancers, but was detected in 1 of the primary unknown neck metastases.
CONCLUSION: In situ hybridization using a digoxigenin-labeled Epstein-Barr virus-encoded small RNA probe is useful for the differential diagnosis of metastasized LNs when the primary site is unknown.